Literature DB >> 27408373

Aggressive Lymphomas Diagnosed in the Bone Marrow: Two Illustrative Cases.

Rekha Bhat1, Swati Pai2, Kunal Das3, Ashish Dixit3.   

Abstract

Lymphomas with subtle patterns in the marrow can be a diagnostic challenge, unless a high index of suspicion is maintained. We present two patients with aggressive lymphomas who presented with cytopenias and the subsequent bone marrow examinations yielded surprising results. These cases highlight the potential usefulness of a bone marrow examination in the diagnosis of lymphomas in the absence of nodal or other tissue specimens.

Entities:  

Keywords:  HSTL; Hepatosplenic T-cell lymphoma; IVLBCL; Intravascular large B cell lymphoma

Year:  2015        PMID： 27408373      PMCID： PMC4925492          DOI： 10.1007/s12288-015-0520-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  20 in total

1.  Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis.

Authors:  M Ponzoni; G Arrigoni; V E Gould; B Del Curto; M Maggioni; A Scapinello; S Paolino; A Cassisa; C Patriarca
Journal:  Hum Pathol       Date:  2000-02       Impact factor: 3.466

2.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

3.  Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia.

Authors:  Yi-Hua Chen; Amy Chadburn; Andrew M Evens; Jane N Winter; Leo I Gordon; Anjen Chenn; Charles Goolsby; Loann Peterson
Journal:  Am J Clin Pathol       Date:  2011-08       Impact factor: 2.493

4.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.

Authors:  Maurilio Ponzoni; Andrés J M Ferreri; Elías Campo; Fabio Facchetti; Luca Mazzucchelli; Tadashi Yoshino; Takuhei Murase; Stefano A Pileri; Claudio Doglioni; Emanuele Zucca; Franco Cavalli; Shigeo Nakamura
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

Review 5.  Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.

Authors:  E Weidmann
Journal:  Leukemia       Date:  2000-06       Impact factor: 11.528

6.  Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.

Authors:  S Yegappan; R Coupland; D A Arber; N Wang; R Miocinovic; R R Tubbs; E D Hsi
Journal:  Mod Pathol       Date:  2001-11       Impact factor: 7.842

Review 7.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

8.  Hepato-splenic gammadelta T-cell lymphoma: a rare entity mimicking the hemophagocytic syndrome.

Authors:  A Nosari; P L Oreste; A Biondi; M C Costantini; L Santoleri; L Intropido; G Muti; E Pungolino; L Gargantini; E Morra
Journal:  Am J Hematol       Date:  1999-01       Impact factor: 10.047

9.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors:  Julie Vose; James Armitage; Dennis Weisenburger
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.